tiprankstipranks
The Fly

Sanara MedTech sees Q4 revenue $25.7M-$26.2M, consensus $23.75M

Sanara MedTech sees Q4 revenue $25.7M-$26.2M, consensus $23.75M

“Our team delivered strong execution with respect to our growth strategy during the fourth quarter of 2024, enabling Sanara to achieve our thirteenth consecutive record net revenue quarter, with growth expected to be at least 45% year-over-year,” stated Ron Nixon, Sanara’s executive chairman and CEO. “Our revenue performance benefited from impressive sales of BIASURGE during the quarter, due in part to shortages of IV fluids and saline solutions in the broader healthcare industry related to Hurricane Helene. These temporary shortages led to exceptionally strong demand from both new and existing customers, and we estimate that our BIASURGE sales in the fourth quarter of 2024 included approximately $1.8 million of revenue that we believe is attributable to this unique situation. We were proud to support our customers during this period of disruption and, importantly, we expect to report strong net revenue growth in the fourth quarter excluding the benefit related to this unique demand.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1